In response to a series of fatal child deaths linked to toxic cough syrups, India has rolled out a robust digital oversight system — the Online National Drug Licensing System (ONDLS). Spearheaded by the Central Drugs Standard Control Organisation (CDSCO), this system is designed to track high-risk pharmaceutical solvents in real time, ensuring that only verified, safe ingredients are used in medicine manufacturing across the country. This urgent reform underscores India’s renewed focus on pharmaceutical safety and accountability, particularly in the wake of rising international concerns about drug quality.
Trigger
- The launch of ONDLS was catalysed by multiple deaths of children in Madhya Pradesh, which were traced back to cough syrups contaminated with diethylene glycol (DEG) — a highly toxic industrial solvent.
- Investigations revealed major gaps in quality control and ingredient traceability, prompting alarm from both domestic authorities and the World Health Organization (WHO).
- DEG has been linked to several mass poisoning incidents in India since the 1970s, sparking repeated calls for tighter regulation. The current fatalities renewed pressure on the Ministry of Health to implement systemic reforms.
Key Features of ONDLS
The ONDLS is a centralised digital platform designed to:
- Monitor and license pharma-grade solvent production.
- Track each batch from manufacturing to end-user level.
- Verify documentation, including certificates of analysis.
- Automatically block unverified or non-compliant batches.
Originally launched to digitise licensing, ONDLS has now been enhanced to focus on end-to-end ingredient traceability, especially for liquid formulations like syrups where contamination risks are high.
